TQB3909: when a "technically qualified" BCL-2 inhibitor arrives two or three years late

In almost every press release for a domestic BCL-2 inhibitor you can find phrases like "filling a gap" and "domestic breakthrough". Two years ago that might still have held up. But for TQB3909, the reality in mid-2026 is — the BCL-2 door has already been knocked open three times by others.

Line them up by approval date in the Chinese market: imported venetoclax (AbbVie/Roche) was approved in China for acute myeloid leukemia (AML) at the end of 2020, and on July 3, 2025 further won chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) — but the indication is restricted to adults "who have received at least one prior therapy and have 17p deletion", a narrower population than TQB3909's target; Ascentage Pharma's lisaftoclax (Lishengtuo, APG-2575) received conditional approval for CLL/SLL on July 10, 2025, officially described as "the first domestically originated BCL-2 and the world's second"; BeiGene's sonrotoclax (Baiyueda, BGB-11417) was approved on January 6, 2026 for both CLL/SLL and mantle cell lymphoma (MCL), officially described as "China's second in-house BCL-2 and the world's third", and on May 13, 2026 further received FDA accelerated approval for relapsed/refractory MCL (after ≥2 prior lines including a BTK inhibitor) — moving from "among the first launched in China" toward global commercialization and widening its lead further.

And TQB3909? Its registrational CLL/SLL Phase 3 (registration no. CTR20261546) was only publicly announced as started in April 2026; but according to CDE information in mid-July, it has already entered the marketing application process and is proposed for priority review, for adults with CLL/SLL who have received at least one prior systemic therapy containing a BTK inhibitor. That is, launch is in sight and the pace is faster than outsiders thought. Even so, when it enters the Chinese market it will at best be "the third domestic and fourth overall" BCL-2. This is not wordplay but the first-principles fact that determines this asset's commercial ceiling — which is why this article will not use any unqualified "first" or "leading" throughout.

First, the parent. Chia Tai Tianqing is the core subsidiary of Sino Biopharmaceutical (01177.HK), which had 2025 revenue of RMB 31.834 billion (+10.3% year on year), innovative product revenue of RMB 15.22 billion (share rising to 47.8%), adjusted net profit attributable to shareholders of RMB 4.54 billion, a gross margin of 82.1% and a market capitalization of about US$12.7 billion. This is a genuine large Chinese pharma — its flagship oncology product anlotinib (Focus V) has won 9 indications, and its commercial team and hospital network are among the deepest in China's solid tumor field.

Now the asset. TQB3909 is an oral, highly selective BCL-2 inhibitor; like venetoclax it is a BH3 mimetic — binding BCL-2 protein to release pro-apoptotic factors and induce tumor cell apoptosis. It uses a daily ramp-up dosing regimen to prevent tumor lysis syndrome (TLS), with a recommended Phase 2 dose of 400 mg once daily taken after food. Its molecular scaffold differs from venetoclax, and CTTQ owns its own compound patent family.

Notably, TQB3909 is purely in-house and purely China-developed — no out-licensing or in-licensing collaboration of any kind, no US/European clinical trials, and no record of communication with FDA/EMA. It is not alone in CTTQ's hematologic oncology pipeline: alongside it are the in-house JAK inhibitor rovadicitinib (TQ05105), the oral proteasome inhibitor TQB3602 and the kinase inhibitor TQB3702, leaving room for in-group combinations — a point expanded on later.

Laying out the data read out so far, TQB3909's single-agent activity in CLL/SLL is indeed not weak:

On safety, non-hematologic adverse reactions were dominated by diarrhea (55.9%), hyperuricemia (42.6%) and hyperbilirubinemia (36.8%), mostly grade 1–2; hematologic toxicity was the main grade ≥3 event; serious treatment-related adverse events were 8.8%, discontinuations due to adverse events 4.4%, with no dose-limiting toxicity and the maximum tolerated dose not reached — under the daily ramp-up regimen, TLS risk was generally manageable.

The judgment in this section needs revising in light of the latest regulatory progress. TQB3909's registrational Phase 3 (CTR20261546) was publicly announced in April 2026, with a sample size of about 128 patients, a primary endpoint of progression-free survival assessed by an independent review committee (IRC-PFS), and a control arm of "investigator's choice regimen". The design itself is pragmatic: IRC-PFS is widely accepted by CDE in CLL, and independent review fits regulatory preferences; but an "investigator's choice" comparator is highly heterogeneous and open-label, which somewhat weakens the persuasiveness of the evidence.

The key is — it is no longer just "running a Phase 3". According to CDE information in mid-July, TQB3909 has entered the marketing application process and is proposed for priority review, for adults with CLL/SLL who have received at least one prior systemic therapy containing a BTK inhibitor. Under CDE procedures, priority review requests are submitted together with the marketing authorization application, so at a minimum it can be confirmed that a marketing application has been filed. Two nuances should be noted: first, the status is currently "proposed", not yet formally granted; second, that Phase 3 is then more likely to play a confirmatory role (whether it will be arranged as a post-marketing study still awaits further regulatory information).

First approvals usually enjoy a 12–24-month exclusivity window and a first-mover position in NRDL negotiation. TQB3909 falling at the back of the queue means that at launch it will face three rivals already priced and possibly already on or entering the NRDL — its price ceiling will be held down by those ahead of it.

For a large pharma like CTTQ playing latecomer, the biggest trump card is its own commercial platform — using an already-built hospital network, medical promotion team and portfolio synergy to dilute the commercialization cost of a late molecule, turning a market where others cannot make a positive return into one that does. This is the core logic of the "Hengrui-style" playbook. The question is how much of this card TQB3909 can actually play.

The score has to be discounted, for three reasons:

Fortunately there is no self-cannibalization within the portfolio — CTTQ has only this one BCL-2, so no same-class infighting; in-house combination partners are all complementary rather than conflicting. Platform synergy is "moderate to weak", but at least not negative.

Pulling the camera to the tumor-type level, the Chinese hematologic oncology market differs from the West in several ways that cannot be copied over directly, and these directly determine TQB3909's commercial logic:

First, CLL is a "small disease" in China. The incidence mentioned above — only a tenth of the West's and 3–5% of non-Hodgkin lymphoma — means any estimate that multiplies Western CLL drug sales by population ratio will severely overestimate the Chinese market. Median age at diagnosis for Chinese patients is about 60–63 (real-world cohorts mostly report around 61, about ten years younger than Western patients), five-year survival is about 70.5%, and the patient base is small.

Second, the first-line position is locked up by BTK inhibitors. Four BTK inhibitors — zanubrutinib, orelabrutinib, ibrutinib and acalabrutinib — dominate first-line CLL treatment in China, and most are already on the NRDL. The main slot for BCL-2 inhibitors in China is second line and beyond, especially after BTK inhibitor failure — a narrower position with more concentrated competitors.

Third, the direction of evolution is "combination". Global CLL treatment is moving from monotherapy toward fixed-duration BCL-2 + BTK inhibitor combinations (e.g. the Phase 3 CELESTIAL study of sonrotoclax plus zanubrutinib, expected to read out in 2026). This cuts both ways for TQB3909: it has in-house combination partners to tell a combination story, but BeiGene holds a complete combination of in-house "BCL-2 + BTK inhibitor" molecules, positioned earlier and more completely.

If the previous sections were about weaknesses, CMC (chemistry, manufacturing and controls) is one of TQB3909's few clear strengths. It is an oral small-molecule tablet with low process scale-up risk; CTTQ has mature in-house solid dosage lines certified under Chinese GMP and by the EU/FDA, self-controlled with continuous supply, and commercial manufacturing cost (typically 5–10% of price for small molecules) leaves ample margin. In other words, if this drug fails, the reason will certainly not be whether it can be made.

The only thing to point out is that this manufacturing strength currently serves only the domestic market. With no overseas registration and no FDA/EMA on-site inspection record for this product, CTTQ's strong global supply capability is in an "inactive" state for this asset — it is a drug made specifically for the Chinese market.

Putting all the signals together, a reasonable judgment is: TQB3909 is not a high priority in CTTQ's portfolio. It is a latecomer in a crowded lane, targeting a relatively small disease, with commercial synergy limited by the departmental wall of hematology — compared with a solid tumor heavyweight like anlotinib, it looks more like an asset to "round out the pipeline and get done along the way" than a strategic core the company is betting on. Fortunately Sino Biopharmaceutical's pipeline is deep and its cash thick enough that even if this Phase 3 fails, the impact on the company overall is very limited, and delays are entirely affordable. Below, a set of "gates" lays out risks and favorable factors in layers.

The core variable behind this has shifted from "when will Phase 3 read out" to "are the existing single-arm data enough to support conditional approval": if so, launch can move forward substantially; if CDE demands fuller confirmatory evidence, then the enrollment speed of the confirmatory Phase 3 (competing for patients in a small population with multiple BCL-2 and BTK inhibitor trials) becomes the bottleneck again.

Five priority actions for the execution team:

TQB3909 is a classic case of "technically qualified, poorly timed". Nothing is wrong with its molecule, nothing is wrong with its manufacturing, and the company behind it does not lack resources; but it has entered a market already taken by three rivals and small to begin with, and has all but given up global value. For a large pharma like Sino Biopharmaceutical, steadily pushing it to market as a piece of the hematologic oncology portfolio is reasonable; but expecting it to become the next blockbuster is unrealistic. Its ceiling was sealed back in 2025, when others knocked that door open first. What is really worth betting on is its potential as the "backbone" of an in-house combination set — not yet another single-agent BCL-2.